Zobrazeno 1 - 10
of 80
pro vyhledávání: '"Laurence, Sanhes"'
Autor:
Antoine Bonnet, Céline Bossard, Ludovic Gabellier, Julien Rohmer, Othman Laghmari, Marie Parrens, Clémentine Sarkozy, Rémy Dulery, Virginie Roland, Francisco Llamas‐Gutierrez, Lucie Oberic, Luc‐Matthieu Fornecker, Laura Bounaix, Bruno Villemagne, Vanessa Szablewski, Sylvain Choquet, Krimo Bouabdallah, Alexandra Traverse‐Glehen, Mohamad Mohty, Laurence Sanhes, Roch Houot, Thomas Gastinne, Christophe Leux, Steven Le Gouill
Publikováno v:
Cancer Medicine, Vol 11, Iss 19, Pp 3602-3611 (2022)
Abstract Background Intravascular large B‐cell lymphoma (lVLBCL) is a very rare type of large B‐cell lymphoma. Methods We conducted a retrospective study on IVLBCL patients treated from 2000 to 2016 in LYSA cooperative group centers. Results Sixt
Externí odkaz:
https://doaj.org/article/165a9e5eadb84a10857ee905f06a650d
Autor:
Anaïs Schavgoulidze, Alexis Talbot, Aurore Perrot, Titouan Cazaubiel, Xavier Leleu, Salomon Manier, Laure Buisson, Sabrina Mahéo, Laura Do Souto Ferreira, Luka Pavageau, Cyrille Hulin, Jean-Pierre Marolleau, Laurent Voillat, Karim Belhadj, Marion Divoux, Borhane Slama, Sabine Brechignac, Margaret Macro, Anne-Marie Stoppa, Laurence Sanhes, Frédérique Orsini-Piocelle, Jean Fontan, Marie-Lorraine Chretien, Hélène Demarquette, Mohamad Mohty, Hervé Avet-Loiseau, Jill Corre
Publikováno v:
Blood. 141:1308-1315
Cytogenetic abnormalities (CAs) are known to be the preponderant prognostic factor in multiple myeloma. Our team has recently developed a prognostic score based on 6 CAs, with which del(1p32) appears to be the second worst abnormality after del(17p).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66fc2af4eb8ace0f9a991bfe8065a525
https://doi.org/10.1182/blood.2022017863
https://doi.org/10.1182/blood.2022017863
Autor:
Marie Sébert, Aline Renneville, Cécile Bally, Pierre Peterlin, Odile Beyne-Rauzy, Laurence Legros, Marie-Pierre Gourin, Laurence Sanhes, Eric Wattel, Emmanuel Gyan, Sophie Park, Aspasia Stamatoullas, Anne Banos, Kamel Laribi, Simone Jueliger, Luke Bevan, Fatiha Chermat, Rosa Sapena, Olivier Nibourel, Cendrine Chaffaut, Sylvie Chevret, Claude Preudhomme, Lionel Adès, Pierre Fenaux
Publikováno v:
Haematologica, Vol 104, Iss 8 (2019)
High-risk myelodysplastic syndrome/acute myeloid leukemia patients have a very poor survival after azacitidine failure. Guadecitabine (SGI-110) is a novel subcutaneous hypomethylating agent which results in extended decitabine exposure. This multicen
Externí odkaz:
https://doaj.org/article/93e54091d43e44dd9d92e24673ef64a4
Autor:
Christian Recher, Sarah Bertoli, Pierre Peterlin, Romain Guieze, Yohan Desbrosses, Yosr Hicheri, Omar Benbrahim, Martin Carre, Hunault-Berger Mathilde, Anne Banos, Marc Bernard, Emmanuel Gyan, Alain Saad, Safia Chebrek, Gabrielle Roth Guepin, Veronique Dorvaux, Laurence Sanhes, Maria Pilar Gallego Hernanz, Carole Exbrayat, Laure Vincent, Chantal Himberlin, Laetitia Largeaud, Eric Delabesse, Francois Vergez, Norbert Vey, Ariane C Mineur, Célestine Simand, Isabelle Luquet, Arnaud Pigneux
Publikováno v:
Blood. 140:6149-6151
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3ddaaa9c63abe496142e1f724dbe06e5
https://doi.org/10.1182/blood-2022-158665
https://doi.org/10.1182/blood-2022-158665
Autor:
Nicolas Boissel, Francoise Huguet, Thibaut Leguay, Mathilde Hunault, Rathana KIM, Yosr Hicheri, Patrice Chevallier, Marie Balsat, Sébastien Maury, Anne Thiebaut-Bertrand, Florence Van Obbergh, Thomas Cluzeau, Martine Escoffre-Barbe, Nicole Straetmans, Johanna Konopacki, Amine Belhabri, Alban Villate, Florence Pasquier, Ioana Vaida, Laurence Sanhes, Magda Alexis, Cedric Pastoret, Mathlide Lamarque, Laure Farnault, Nathalie Grardel, Celine Berthon, Eric Delabesse, Veronique Lheritier, Norbert Ifrah, Carlos Graux, Yves Chalandon, Emmanuelle Clappier, Herve Dombret
Publikováno v:
Blood. 140:507-509
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8882b4f1623dca887609fc23e431cbe2
https://doi.org/10.1182/blood-2022-159397
https://doi.org/10.1182/blood-2022-159397
Autor:
Guillaume Cartron, Emmanuel Bachy, Hervé Tilly, Nicolas Daguindau, Gian-Matteo Pica, Fontanet Bijou, Christiane Mounier, Aline Clavert, Gandhi Laurent Damaj, Borhane Slama, Olivier Casasnovas, Roch Houot, Krimo Bouabdallah, David Sibon, Olivier Fitoussi, Nadine Morineau, Charles Herbaux, Thomas Gastinne, Luc-Matthieu Fornecker, Corinne Haioun, Vincent Launay, Carla Araujo, Omar Benbrahim, Laurence Sanhes, Remy Gressin, Hugo Gonzalez, Franck Morschhauser, David Ternant, Luc Xerri, Karin Tarte, Delphine Pranger
Publikováno v:
Journal of Clinical Oncology.
PURPOSE Rituximab improves progression-free survival (PFS) and time to next treatment (TTNT) when compared with the watch and wait strategy for patients with low–tumor burden follicular lymphoma (FL). Prolonged rituximab maintenance did not prolong
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7649764f7988251af924e03a3cb0a116
https://doi.org/10.1200/jco.22.02327
https://doi.org/10.1200/jco.22.02327
Autor:
Krzysztof, Mądry, Karol, Lis, Pierre, Fenaux, David, Bowen, Argiris, Symeonidis, Moshe, Mittelman, Reinhard, Stauder, Jaroslav, Čermák, Guillermo, Sanz, Eva, Hellström-Lindberg, Saskia, Langemeijer, Luca, Malcovati, Ulrich, Germing, Mette Skov, Holm, Agnes, Guerci-Bresler, Dominic, Culligan, Laurence, Sanhes, Ioannis, Kotsianidis, Corine, van Marrewijk, Simon, Crouch, Theo, de Witte, Alex, Smith
Publikováno v:
British Journal of Haematology, 200, 4, pp. 451-461
British Journal of Haematology, 200, 451-461
British Journal of Haematology, 200, 451-461
Contains fulltext : 290857.pdf (Publisher’s version ) (Closed access) Information on causes of death (CoDs) and the impact of myelodysplastic syndromes (MDS) on survival in patients with lower-risk MDS (LR-MDS) is limited. A better understanding of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40bc90f101ef2b868e2df6ff974af994
https://doi.org/10.1111/bjh.18542
https://doi.org/10.1111/bjh.18542
Autor:
Emmanuel Gyan, Pierre Fenaux, Pascale Cony-Makhoul, Odile Beyne-Rauzy, Kamel Laribi, Clémence Santana, Bohrane Slama, Jean-Thomas Giraud, Clément Gaudin, Laurence Sanhes, Ana Berceanu, Sophie Dimicoli, Amina Cherait, Berangere Gruson, Groupe Francophone des Myélodysplasies, Jose Miguel Torregrosa, Thibault Comont, Vincent Jachiet, Marie-Agnès Azerad, Mathieu Meunier, Thomas Cluzeau, Claire Guerveno, Pr Lionel Ades, Thierry Guillaume, Ahmad Al Jijakli, Lenaïg Le Clech, Jonathan Broner
Publikováno v:
British Journal of Haematology. 194:336-343
Despite a moderate prevalence in low-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukaemia (CMML), thrombocytopenia remains a risk of severe bleeding and therapeutic options are still limited. There are only a few studies with elt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::019336f92b23a5970214adc9288139fe
https://doi.org/10.1111/bjh.17539
https://doi.org/10.1111/bjh.17539
Autor:
Salomon Manier, Jill Corre, Cyrille Hulin, Kamel Laribi, Carla Araujo, Gian-Matteo Pica, Cyrille Touzeau, Pascal Godmer, Bohrane Slama, Lionel Karlin, Frederique Orsini-Piocelle, Mamoun Dib, Margaret Macro, Laurence Sanhes, Aurore Perrot, Jean Yves Mary, Jerome Lambert, Herve Avet-Loiseau, Philippe Moreau, Xavier Leleu, Thierry Facon
Publikováno v:
Blood. 140:1369-1370
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1a715e53199fbcb22da6b0dcc007b833
https://doi.org/10.1182/blood-2022-159933
https://doi.org/10.1182/blood-2022-159933
Autor:
Sylvain Thépot, Raouf Ben Abdelali, Sylvie Chevret, Aline Renneville, Odile Beyne-Rauzy, Thomas Prébet, Sophie Park, Aspasia Stamatoullas, Agnes Guerci-Bresler, Stéphane Cheze, Gérard Tertian, Bachra Choufi, Laurence Legros, Jean Noel Bastié, Jacques Delaunay, Marie Pierre Chaury, Laurence Sanhes, Eric Wattel, Francois Dreyfus, Norbert Vey, Fatiha Chermat, Claude Preudhomme, Pierre Fenaux, Claude Gardin
Publikováno v:
Haematologica, Vol 101, Iss 8 (2016)
The efficacy of azacitidine in patients with anemia and with lower-risk myelodysplastic syndromes, if relapsing after or resistant to erythropoietic stimulating agents, and the benefit of combining these agents to azacitidine in this setting are not
Externí odkaz:
https://doaj.org/article/dcc821d2ee5a454fb0d4fe2816dcf54e